Last Updated2026-06-02

Market View

₹434.45(▲7.95%)

Reporting PeriodQ4 FY26

BLISSGVSBliss GVS Pharma Limited Forensic Risk Analysis

Name: Bliss GVS Pharma Limited Structural Risk Analysis
Creator: Flagium AI
License: https://creativecommons.org/licenses/by-nc-nd/4.0/

Pharmaceuticals

Risk ClassStable

Market Cap₹2,262 Cr

Primary DriverBalance Sheet Stress

Flagium AI Risk Score

8 / 100

+3 QoQ

Early Deterioration

Sentinel Insight

Financial profile remains stable for now. Weakness is detected in balance sheet stress. No immediate concerns are visible. Risk is increasing at a faster pace.

19.2th %ile (Sector)Accel: +2 Qtrs

Updated2026-06-02

Market View

₹434.45▲7.95%

PeriodQ4 FY26

Score Waterfall
Absolute contribution points of each forensic pillar to the final risk score. Derived from: Sector Baseline + Active Penalties - Mitigation Buffers.

Balance Sheet Stress

+8.0 pts

Final Composite Risk8 / 100

Investment Risk Thesis

Historical Trend

Current risk score has risen from 0 → 8 over 12 quarters.

Expected Direction

⚠ Watch

Primary Deterioration Drivers

Inventory Stress
Working Capital Expansion
Operating Leverage Stress

What to Watch Next Quarter

Operating profit margins
Working capital efficiency
Debt growth

Active Risk Objects (6)

CriticalHigh

Low Interest Coverage

💧 Liquidity & CoverageQuarterlyActive for 1 Qtrs

More Detail

Impact Weight8/15

MomentumDecaying

Last SignalQ4 FY2024

BLISSGVS: Low Interest Coverage Ratio of -1.13x in FY2024 Q4 (Threshold: 2.5x).

"The ability to cover interest is strengthening as earnings improve or debt is retired."

Profit Collapse

📊 Earnings QualityQuarterlyActive for 1 Qtrs

More Detail

Impact Weight8/15

MomentumDecaying

Last SignalQ4 FY2024

BLISSGVS: Net Profit collapsed by 241.8% from FY2023 Q4 to FY2024 Q4.

"Earnings quality is stabilizing. The reliance on non-operational items is receding."

Working Capital Expansion

💧 Liquidity & CoverageAnnualActive for 3 Years

More Detail

Impact Weight10/15

MomentumPersistent

Last SignalQ4 FY2026

Working capital expansion detected: Receivable days increased by -7.6%.

"Early signs of working capital expansion. Receivable or inventory days are creeping up."

Operating Leverage Stress

📊 Earnings QualityAnnualActive for 1 Years

More Detail

Impact Weight10/15

MomentumAccelerating

Last SignalQ3 FY2026

Expenses are consistently growing faster than revenues, creating operational pressure.

"Debt levels are creeping up. Monitor for signs of excessive borrowing for non-core activities."

Inventory Stress

📊 Earnings QualityAnnualActive for 3 Years

More Detail

Impact Weight15/15

MomentumDecaying

Last SignalQ4 FY2025

Inventory growth (6.1%) significantly outpaced revenue growth (3.1%).

"Inventory overhang is clearing. Stock levels are normalizing as sales momentum returns."

Capex Efficiency Stress

📊 Earnings QualityAnnualActive for 1 Years

More Detail

Impact Weight8/15

MomentumDecaying

Last SignalQ2 FY2025

Aggressive Capex (15.3%) amidst slow revenue growth (-0.8%).

"Earnings quality is stabilizing. The reliance on non-operational items is receding."

Risk Trajectory

Loading Chart

Resilience Matrix

Metric	Value	vs Sector	Signal
Volatility (σ)	3.45	7.70	✅ RESILIENT
Sensitivity (ε_s)	1	1.00	✅ RESILIENT
Escalation Prob.	5%	5%	✅ NEUTRAL
Safety Buffer	+58.0	+47.0	✅ RESILIENT

Forensic Benchmark Context: Pharmaceuticals (n=99 peers)

Correlation Analysis
Visualizing the relationship between stock price movement and structural risk objects.

Loading Chart

Share Price

Risk Score (0-100)

Market Performance

₹434.45(+7.95%)

1M Divergence+54.71%

1 Week+14.01%

1 Month+56.98%

6 Months+160.92%

1 Year+226.58%

2 Year+326.35%

3 Year+503.99%

Sector Average (1M)+2.27%

Sentinel Forensic Assessment

ALGORITHMIC RISK PROFILE • NON-ADVISORY

The structural architecture is currently robust. Capital resilience buffers in balance sheet stress remain well-maintained against forensic benchmarks. Systematic scans of core structural metrics confirm the absence of material structural stress. The current structural trajectory supports a stable risk outlook.

BLISSGVS • MARKET STRUCTURE

Stage 2 — Advancing

The company is in a growth phase. Institutional sentiment is highly positive, supported by strong fundamentals and sustained risk reduction.

Stage Transition Prob.99%

Trend QualityStrong

Phase Progression

Phase Progression Score100%

Readiness LabelHigh (Phase Transition Imminent)

Probability of Advancing99%

CoinTree Momentum

Composite Z-Score+4.4945σ

Strong positive momentum leadership

Universe Rank#8 of 2716

Top 0.29% in momentum strength

Timeframe Sparklines

1W+14.0%

1M+57.0%

6M+160.9%

Weinstein Indicators

150 DMA₹208.79

200 DMA₹195.8

150 DMA Slope+11.5491%Rising

Relative Strength+166.40%Leading

Relative Turnover (RTR)1.7056

ParticipationHealthy

PEER COMPARISON

Ranked comparison against sector peers

This company appears relatively stable compared to the Sector Mean (19).

Ticker	Risk Score	Sector %ile	Delta	Flags	Accel	Primary Driver
ABBOTINDIAABBOTINDIA	0	0th	0	0	+0	GovernanceStable
BLISSGVSBliss GVS Pharma Limited	8	19th	+3	6	+2	Balance Sheet StressStable
AARTIDRUGSAarti Drugs Limited	19	51th	-5	11	+0	Competitive PositionStable
AAREYDRUGSAarey Drugs & Pharmaceuticals Limited	23	63th	-5	20	+0	Balance Sheet StressWatch